Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.47 |
| ▸ | RXRB | P28702 | 12/20 | 0.47 |
| ▸ | RXRG | P48443 | 12/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933986 | 0.91 | RXRA (0.56) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL3933465 | 0.83 | CYP3A4 (0.47) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6343446 | 0.83 | CYP3A4 (0.44) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6343404 | 0.80 | SMN1; SMN2 (0.47) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6335047 | 0.79 | RXRA (0.56) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6337770 | 0.79 | SMN1; SMN2 (0.46) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6343496 | 0.78 | RXRA (0.55) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6344748 | 0.78 | RXRA (0.55) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6347601 | 0.78 | RXRA (0.55) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL6337777 | 0.77 | SMN1; SMN2 (0.47) | RXRARXRBRXRGCYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430023-B1 | SUBSTITUIED UREA RETINOID AGONISTS II | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6838472-B2 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1430023-A1 | SUBSTITUIED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-20030125383-A1 | Substituted urea retinoid agonists | ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) LLC | 2003-07-03 | — | — | US | disclosed |
| WO-2003024920-A1 | SUBSTITUTED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125383-A1 | Substituted urea retinoid agonists | RXRA, RXRG, RARG | RXRA 1/4885RXRB 4/4885RXRG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.